Article info

Download PDFPDF

Original research
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

Authors

  1. Correspondence to Dr Ami N Shah; amishah{at}northwestern.edu
View Full Text

Citation

Shah AN, Flaum L, Helenowski I, et al
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

Publication history

  • Accepted January 16, 2020
  • First published February 13, 2020.
Online issue publication 
February 13, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.